

ozanimod (ZEPOSIA)

Diagnoses Considered for Coverage:

- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
- Moderately to severely active ulcerative colitis (UC) in adults

Coverage Criteria:

For diagnosis of multiple sclerosis:

- Not being used in combination with another multiple sclerosis disease modifying therapy, **and**
- Dose does not exceed 0.92 mg per day, **and**
- Inadequate response or intolerable side effects with TWO preferred MS disease-modifying agents:
 - Extavia,
 - fingolimod,
 - dimethyl fumarate (Tecfidera)
 - glatiramer, Glatopa or Copaxone

For diagnosis of ulcerative colitis:

INITIAL AUTHORIZATION

For request with prior targeted immunotherapies (i.e. anti-TNFs) treatment

- Patient is at least 18 years of age, **and**
- Inadequate response or intolerable side effect with two preferred agents for UC: Humira, Hadlima, Rinvoq, Stelara, and Xeljanz/Xeljanz XR) OR contraindication to all preferred agents, **and**
- Not being used in combination with other targeted immunotherapies (i.e., anti-TNFs, interleukin inhibitors, JAK inhibitors), **and**
- Dose does not exceed 0.92 mg per day

REAUTHORIZATION

- Patient has continued response to therapy, **and**
- Dose does not exceed 0.92 mg per day.

Coverage Duration:

MS: Length of benefit

UC: 10 weeks

Effective Date: 01/03/2024